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Abstract
Pulmonary arterial hypertension (PAH), a debilitating and incurable disease, 
predominantly develops in women. Estradiol metabolism leads to the production 
of numerous metabolites with different levels of estrogenic activity and very often 
opposing biological effects. Dysregulated estradiol metabolism was recently linked 
to the penetrance, progression, and prognosis of the disease. Ongoing clinical trials 
are examining the effects of estradiol synthesis/signaling inhibition in patients with 
PAH. In this chapter, the effects of sex, sex hormones, and estradiol metabolism 
on the healthy pulmonary circulation and vascular pathobiology are discussed in 
the light of estradiol metabolism as potential pharmacological target in PAH. The 
effects of estrogens and their metabolites on vascular pathobiology and disease 
progression, their involvement in PAH-associated diseases, and the pros and cons 
for interventions at different levels of estradiol metabolism are discussed. Finally, 
we propose that 2-methoxyestradiol (2ME), a major non-estrogenic metabolite of 
estradiol, mediates at least in part the beneficial effects of estradiol and that 2ME 
exhibits opposing effects to estradiol on several processes relevant to the underlying 
pathophysiology of PAH, including angiogenesis, metabolic reprograming, inflam-
mation, and immunity. Based on cellular and in vivo effects, 2ME should be viewed 
as a disease modifier in women with PAH.
Keywords: pulmonary hypertension, estradiol metabolism, 2-methoxyestradiol, 
angiogenesis, inflammation
1. Introduction
Pulmonary arterial hypertension (PAH) is a progressive incurable disease of pul-
monary vasculature that ultimately leads to failure of the right ventricle (RV) and 
death. Notably the disease predominantly develops in women. The first report in 
1951 by Dr. David Dresdale and colleagues from Maimonides Hospital of Brooklyn 
on hemodynamic aspects of primary pulmonary hypertension (PH) included three 
25- to 35-year-old women [1]. Similarly, in 1952 in the second seminal report on 
PAH, British cardiologist Paul Wood recognized that this is “...relatively rare disease, 
usually encountered in women between 20 and 30, but may be met at any age and 
in either sex...” [2]. These early observations of female preponderance of PAH were 
confirmed by epidemiological studies conducted in the last two decades, and the 
data from various registries worldwide report a female-to-male ratio (F:M) ranging 
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from 2:1 to 4:1 [3–9] and up to 4:1 to 9:1 for connective tissue disease [10–12]. 
However, with aging the female preponderance of disease disappears, and an M:F 
of only 1.2:1.0 has been reported in elderly PAH patients [13]. The latter strongly 
suggests involvement of female sex hormones in the development of PAH.
1.1 Vascular pathobiology in PAH
Pulmonary vascular remodeling is a pathological hallmark of PAH. Vascular 
morphological manifestations of the disease include (i) concentric and asymmetric 
obliterative proliferation of endothelial cells (ECs) and distal formation of multicel-
lular plexiform lesions (PLXL); (ii) the muscularization of distal non-musculinized 
precapillary vessels; (iii) adventitia remodeling in form of fibrosis, inflammation, 
and perivascular edema; and (iv) PLXL, dilation lesions, and arteritis classified 
as complex lesions [14]. Three-dimensional analysis of vascular lesions in patients 
with severe PAH reveals the existence of two major phenotypes of ECs. The normal 
quiescent apoptosis-sensitive ECs are located in the peripheral areas of the lesion, are 
negative for phosphorylated MAPK, and have a high expression of p27kip1 (a marker 
of slow proliferation). The highly proliferative apoptosis-resistant cells in the central 
core of the vascular lesion have elevated MAPK activity and increased expression of 
HIF-1α, VEGF protein, and VEGF-2 receptor and low expression of p27kip1 [15, 16].
Both inflammation and immune cell response are recognized as important 
pathogenic factors in PAH [17–19]. For example, in experimental PH perivascular 
inflammation, due to macrophages, mast cells, and T and B lymphocytes, precedes 
vascular remodeling and elevated pulmonary pressure [20], and in PAH patients, 
the degree of perivascular infiltration by immune cells correlates with vascular 
remodeling and pulmonary artery pressure [21]. As discussed below, inflamma-
tion may markedly influence estradiol metabolism, and vice versa, estrogens and 
their metabolites may instigate, perpetuate, or inhibit inflammation and modulate 
immune cell responses in PAH.
2.  Opposing effects of estradiol and 2-methoxyestradiol on estrogen 
metabolism
Since our first report that 2ME, a major non-estrogenic metabolite of 
17β-estradiol (E2), attenuates the development and progression of monocrotaline 
(MCT)-induced PH and that estrogens may be pathogenic in PAH [22], a growing 
body of evidence suggests the involvement of dysregulated estradiol metabolism and 
elevated estrogen levels in the development, progression, and prognosis of PAH.
2.1 Increased estradiol production in PAH
Formation and metabolism of estrogens are complex (Figure 1). The pivotal 
precursors for synthesis of both androgens and estrogens are dehydroepiandros-
terone (DHEA) and its biologically inactive sulfate (DHEA-S). DHEA is produced 
in the adrenal gland of men and postmenopausal women and in the ovaries and 
placenta of premenopausal women. DHEA, the most abundant steroid in circula-
tion, is also produced by peripheral conversion from circulating DHEA-S. DHEA is 
transported into cells by organic anion transporters (OATPs) that are expressed in 
various tissues including the endothelial and inflammatory cells and lungs [23–25]. 
The delicate balance between DHEA and DHEA-S is controlled by the relative 
activity of sulfotransferase (DHEA → DHEA-S) and sulfatase (DHEA-S → DHEA) 
[26]. Both DHEA and DHEA-S are protective in experimental models of pulmonary 
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hypertension [27–31] including models of angioproliferative PH [32, 33]. Recently, 
lower DHEA-S and higher E2 levels have been linked to a greater risk of PAH and 
worse hemodynamics, functional status, and greater risk of death [34, 35]. Notably, 
DHEA improves PAH in patients with obstructive pulmonary disease [36], a finding 
supporting the potential therapeutic application of DHEA in PAH patients. DHEA 
is an over-the-counter supplement with no major side effects; however, its safety 
during chronic use in pharmacological doses is unknown. One potential adverse 
effect in this regard would be increased circulating/tissue E2 levels that may exacer-
bate endothelial remodeling and inflammation (infra vide).
Aromatase (encoded by the CYP19A1 gene) is the rate-limiting enzyme catalyz-
ing the conversion of upstream androgenic precursors to estrogens (androstene-
dione → estrone and testosterone → E2; Figure 1). In premenopausal women, 
estrogens are produced predominantly in the ovarian granulosa cells and are 
released into the bloodstream where they act primarily in an endocrine fashion. In 
postmenopausal women and in men, estrogen synthesis takes place in extra-gonadal 
tissues (liver, heart, skin/fat tissue, and brain) where estrogens act mainly as 
paracrine or autocrine factors. Aromatase expression in these various sites is under 
the control of tissue-specific promoters regulated by different cohorts of transcrip-
tion factors. Therefore, aromatase activity differs substantially in various tissues and 
organs in health and disease [37]. Notably, human endothelium expresses a complete 
aromatase-estrogen-E2 receptor system [38], and increased expression of aromatase 
has been reported in hPASMCs from female PAH patients and in the lungs of female 
rats and mice with angioproliferative PH [39]. Increased aromatase activity and 
plasma E2 levels seen in both men and women with advanced liver disease is associ-
ated with increased risk of portopulmonary PAH [40], and increased aromatization 
of androgens and elevated E2 levels have been reported in postmenopausal women 
and in men with PAH [34, 35]. Noteworthy, E2 stimulates aromatase activity and by 
increasing aromatization of androgen precursors may augment its own production 
as well as production of E1. Because of the importance of this enzyme in estrogen 
synthesis, blocking aromatase activity is an important pharmacological tool used for 
the treatment of estrogen-dependent diseases (breast cancer, endometriosis, and 
Figure 1. 
Dehydroepiandrosterone is the most abundant steroid in circulation that is also produced by peripheral 
conversion from its circulating inactive sulfated metabolite DHEA-S. The balance between inactive sulfated 
sex steroids and sex steroids and their biologically active metabolites and metabolic precursors is controlled 
by sulfatase (STS) and sulfotransferase (SULT). Aromatase is a key enzyme in estrogen production because 
this enzyme controls aromatization of androgenic precursors to estrogens and intracrine production of 
estrogens. 2-Hydroxylation/methylation pathway of estrogen metabolism produces non-estrogenic metabolites 
with opposite effects to maternal estrogens. Hydroxylation of estradiol (E2) at C4 and C16 position leads to 
production of highly estrogenic metabolites with proliferative, pro-inflammatory, and angiogenic properties.
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endometrial cancer). Anastrozole (a third-generation aromatase inhibitor) reduces 
E2 levels and attenuates PH in female mice exposed to hypoxia [39] and in Sugene 
5416 + hypoxia rats with angioproliferative PH [39, 41]. Moreover, when combined 
with the selective estrogen receptor degrader fulvestrant, anastrozole reverses PH 
in BMPR2-mutant mice [42]. Likewise, in PAH patients treatment with anastrozole 
reduces elevated E2 levels by 40% and E1 levels by 70% and significantly increases 
functional capacity, i.e., 6-minute-walk distance [43]. Notably, E2 augments gonadal 
aromatase activity, and by increasing aromatization of androgens, E2 may augment 
its own production as well as that of other estrogens [44]. Inflammation and inflam-
matory cytokines upregulate aromatase activity, and TNFα is one of the most potent 
inducers of aromatase. In contrast to estrogens that do not have effect on TNFα 
induction of aromatase [45], 2ME inhibits both basal and TNFα-stimulated aroma-
tase activity [45–47].
In addition to aromatase, another potential source of increased estrogen produc-
tion in PAH is the “sulfatase pathway.” In addition to DHEA-S, other substrates for 
STS are biologically inactive estrone sulfate (E1-S) and estradiol sulfate (E2-S), and 
sulfatase plays a key role in intracrine regeneration of biologically active E2 and E1 
(Figure 1). Inflammatory cytokines increase STS activity. More importantly, STS 
expression is stimulated by estrogens via estrogen receptor alpha (ERα) signaling, 
and at least in breast cancer, STS is upregulated by the elevated local E2 levels [26]. 
Thereby, in an inflammatory environment, E2 through feed-forward mechanisms 
may increase its on production via both the sulfatase and aromatase pathways 
(Figure 2), as implicated by elevated aromatase activity and E2 levels in both 
experimental PH [39] and in men and women with PAH [34, 35, 40].
2.2 Dysregulated estradiol metabolism in PAH
Once formed, E2 is primarily metabolized by oxidation at C2, C4, and C16 posi-
tions and converted to metabolites with different estrogenic activities and diverse 
(often opposite) biological effects. In humans, E2 hydroxylation is mediated by 
Figure 2. 
Opposing effects of E2 and 2ME on estrogens and arachidonic acid metabolism. Inflammation and dual 
metabolic activity of CYP1B1 instigate estradiol feed-forward mechanisms that involve sulfatase, aromatase, 
COMT, and CYP1B1 (red arrows). Thereby, the increased E2 and arachidonic acid pro-inflammatory 
metabolites may contribute to the development of inflammatory and angioproliferative phenotypes 
in women. In contrast, 2ME by inhibiting CYP1B1 activity, macrophage influx/activation, and pro-
inflammatory cytokine induction of estrogen-producing enzymes (blue arrows) balances inflammation 
and E2 production and its metabolisms into mitogenic pro-inflammatory and angiogenic metabolites. 
CYP1B1 activation results in production of pro-inflammatory arachidonic acid metabolites (black arrows). 
COMT = catechol-O-methyltransferase; CYP = cytochrome p450 enzymes; EETs = epoxyeicosatrienoic acids; 
HETEs = hydroxyeicosatetraenoic acids; sEH = soluble epoxide hydrolase, degrades EETs.
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multiplying CYP450 enzymes (CYP1A1/1A2/3A4/1B1) with 2-hydroxyestradiol (2HE) 
being the main metabolite; however, 4-hydroxyestradiol (4HE; Figures 1 and 2) is 
formed to a lesser degree (~5%). This is followed by methylation of hydroxyl groups 
catalyzed by catechol-O-methyl transferase (COMT). The hydroxylation/methylation 
pathway is a major metabolic pathway that accounts for ~50% of E2 metabolism. It 
largely takes place in the liver and leads to production of 2ME, a major non-estrogenic 
metabolite with antiproliferative, anti-angiogenic, and anti-inflammatory effects 
[48]. In addition to hepatocytes and numerous cancer cell lines, conversion of E2 to 
downstream 2HE and 2ME takes place in cardiovascular and renal compartments 
[48], and a solid line of evidence suggests that 2ME mediates the antiproliferative 
effects of E2 in cardiovascular and renal cells [49].
Notably, the protective effects of E2 in experimental PH are mediated, at least 
in part, by 2ME [50, 51]. Furthermore, it seems that in highly proliferative states, 
2ME may oppose estrogen-driven proliferation. For example, in highly proliferative 
human leiomyoma cells (hLCs) characterized by doubled ERα signaling (inherently 
regulated by microtubule dynamics) [52], COMT overexpression or treatment 
with 2ME stabilizes microtubules, attenuates E2-induced proliferation, inhibits 
ERα signaling, and reduces HIF-1α and aromatase expression in hLCs [53, 54]. 
Unfortunately, it seems that elevated E2 levels seen in PAH may adversely affect 
both hepatic and extrahepatic 2ME production. In this regard, men have higher 
COMT activity than women [55, 56], and sex hormones regulate COMT activity 
that is highly expressed in human and rat lungs [57, 58]. The exposure to E2 reduces 
hepatic COMT activity in rats [59, 60]; in vitro E2 decreases COMT transcription, 
activity, and protein levels [61, 62]; and tamoxifen, by antagonizing E2, increases 
COMT activity in peripheral tissues [63]. Together, these findings suggest that 
reduced COMT activity by elevated E2 and subsequent decreased in 2ME produc-
tion may render women more susceptible to the development of PAH. At present 
it is unknown whether there is reduced 2ME production in PAH. Yet, reduced 2ME 
production has been linked to the development of preeclampsia [64], increased 
sensitivity to angiotensin II [65], and insulin resistance [66].
2.3  Opposing effects of estradiol and 2-methoxyestradiol on CYP1B1 activity 
and estrogen and arachidonic acid metabolism
E2 and 2ME have opposing effects on CYP1B1, another E2 metabolizing enzyme 
implicated in pathogenesis of PAH. Human CYP1B1 mRNA and protein are consti-
tutively expressed in the lung and in VSMCs and ECs [67]. CYP1B1 may facilitate E2 
oxidation at C4 and C16, thus producing highly estrogenic and reactive metabolites 
4-hydroxyestradiol (4HE) and 16α-hydroxyestrone (16αHE1). Experimental and 
human data suggest a major pathogenic role for CYP1B1 and 16αHE1 in PAH. In 
this regard, CYP1B1 increases the risk of PAH and RV dysfunction in humans and 
plays a pathogenic role in the 16αHE1-BMPR2 interaction in experimental PH 
[68–76]. Notably, E2 and 2ME have divergent effects on CYP1B1 activity. Estradiol 
is not only a substrate for CYP1B1, but also it is transcriptional activator of CYP1B1 
[77]. In contrast, in vitro 2ME exerts feedback inhibition on CYP1B1 activity [78]. 
Moreover, 2ME inhibits aryl hydrocarbon receptor-mediated induction of CYP1B1 
and reduces CYP1B1 production of reactive metabolites. In vivo, 2ME significantly 
inhibits CYP1B1 expression and attenuates pressure overload-induced cardiac 
remodeling [78, 79]. In vivo CYP1B1 inhibition by 2ME reduces biosynthesis of 
mid-chain hydroxyeicosatetraenoic acids (HETEs) [79], suggesting a significant 
role for CYP1B1 in arachidonic acid metabolism. Indeed, due to its lipoxygenase-like 
activity, CYP1B1 facilitates arachidonic acid metabolism into HETEs and epoxyeico-
satrienoic acids (EETs) [80]. In the pulmonary vasculature, EETs and HETEs have 
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vasoconstrictive, inflammatory, and mitogenic/angiogenic effects and have been 
implicated in the development of experimental hypoxic PH [81–84]. Noteworthy, in 
PAH patients increased production of HETEs correlates with a poor prognosis [85]. 
E2 not only stimulates production of HETEs and EETs but also by inhibiting expres-
sion/activity of soluble epoxide hydrolase (sEH) [86] suppresses the degradation of 
EETs. Several lines of evidence link low sEH activity to the pathophysiology of PH: 
(1) the lungs from PH patients express no/little sEH; (2) E2-, genetic-, and pharma-
cologically induced downregulation of sEH potentiates hypoxic vasoconstriction; 
(3) hypoxia downregulates sEH; and (3) sEH−/− mice have exacerbated pulmonary 
vascular remodeling when exposed to chronic hypoxia [87–89]. Therefore, elevated 
E2 levels in PAH through a feed-forward mechanism may shift both E2 and AA 
metabolism toward production of pro-inflammatory/angiogenic/mitogenic metab-
olites. Based on its inhibitory effects, 2ME should suppress the production of these 
pathogenic E2 and AA metabolites (Figure 2).
3.  Divergent effects of 2ME and estradiol in pulmonary endothelium  
in PAH
Dysregulated angiogenesis with formation of occlusive and plexiform lesions 
is a hallmark of PAH. Although estrogens provide protection in healthy systemic 
vascular beds, they have opposite effects on malignant proangiogenic/highly prolif-
erative vessels [90] that share many similarities with vascular changes in PAH. The 
highly proliferative apoptosis-resistant cells in the central core of vascular lesions 
in PAH have elevated MAPK activity; increased expression of HIF-1α, VEGF 
protein, and VEGF-2 receptor; and low expression of p27kip1 (marker of low cell 
growth) [15, 16]. In human pulmonary artery ECs (hPAECs) and at physiological 
concentrations (1–10 nM), E2 (1) stimulates cell proliferation [91]; (2) promotes 
the phosphorylation of p42/44 and p38 MAPK via ERs; (3) downregulates the cell 
cycle inhibitor p27Kip1; (4) stimulates cell migration; (5) induces HIF-1α expres-
sion and VEGF synthesis; and (6) protects against apoptosis [92–94]. Also, E2 
stimulates proliferation of human pulmonary artery vascular smooth muscle cells 
(hPASMCs). In canine pulmonary arterial segments, E2 tends to inhibit prolifera-
tion of PASMCs in segments with intact endothelium but significantly enhances 
proliferation in segments stripped of endothelium [95], suggesting opposite effects 
of E2 in intact versus injured pulmonary vessels. Thereby, in the pulmonary vas-
culature exposed to known and unknown multiple hits, estrogens may potentiate 
pathological endothelial remodeling in PAH (Figure 3).
In contrast to E2, it is well established that 2ME has strong anti-angiogenic, 
antiproliferative, and pro-apoptotic effects [96] and thereby may prevent PAH or 
inhibit the progression of PAH. In this regard, of particular importance for PAH 
are the effects of 2ME on the HIF-1α/VEGF axis. One of the most consistently 
reported effects of 2ME is HIF-1α downregulation, and 2ME has been increasingly 
used as pharmacological tool to inhibit HIF-1α in numerous studies outside the PAH 
field. HIF-1α transcriptional activity regulates more than 40 genes and respective 
proteins, including those that play a key role in vascular reactivity and angiogenesis 
[97, 98]. The role of HIF-1α in PAH is supported by multiple findings including the 
following: (1) obliterative endothelial lesions in severe PH in humans overexpress 
HIF-1α [15]; (2) in experimental PH there is similar increase in HIF-1α that cor-
relates with the development of PH and pulmonary vascular remodeling and RV 
hypertrophy; (3) heterozygous deficiency in HIF-1α protects against the develop-
ment of PH [99, 100]; and (4) pathologic normoxic HIF-1α signaling activation 
leads to the glycolytic shift (the Warburg effect) in highly proliferative ECs [101].
72-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier
DOI: http://dx.doi.org/10.5772/intechopen.86812
Hypoxia stimulates 2ME formation which inhibits the production of hypoxia-
driven angiogenesis and angiogenic cytokines (VEGF and FGF-2) [31, 102]. Therefore, 
2ME should be viewed as a local modulator that fine-tunes the rate of angiogenesis. 
Recent studies in experimental PH support the notion of 2ME as a local anti-angio-
genic factor in PAH and E2 as promoter of angiogenesis. For example, (1) basal HIF-1α 
protein expression is higher in female hPASMCs than in males; (2) the antimitogenic 
effects of 2ME in hPASMCs are associated with reduced HIF-1α expression; (3) 2ME 
attenuates intermittent and chronic hypoxia-induced PH [22, 103, 104]; (4) in both 
male and female hypoxic PH rats, 2ME attenuates the disease while decreasing HIF-1α 
protein expression [103]; (5) female rats with Sugene 5416 + hypoxia (SU+Hx)-
induced PH have more severe occlusive and plexiform lesions and sporadically develop 
grade 6 lesions (necrotizing arteritis); (6) E2 exacerbates angioproliferative lesions 
and perivascular inflammation in ovariectomized SU+Hx rats [105, 106]; and (7) in 
intact female SU+Hx rats, 2ME, but not E2, exhibits therapeutic effects [107]. The 
effects of 2ME in PAH patients are unknown. Yet, at least in experimental angioprolif-
erative PH, 2ME could be viewed as biological antagonist of E2 in the endothelium and 
as a modifier of “dysregulated angiogenesis.”
4. Metabolic reprograming and 2ME in PAH
The major metabolic changes that take place in PAH occur in the form of the 
shift from oxidative phosphorylation to glycolysis. Known as the Warburg effect, 
this event is frequently observed and has been systematically investigated in cancer 
tissue. Notably, the Warburg effect has also been reported in pulmonary vascula-
ture cells in PAH patients [108] and linked to highly proliferative, angiogenic, and 
apoptosis-resistant cancer cells and vascular cells in PAH. Not surprisingly, the 
Figure 3. 
In the injured highly proliferative/angiogenic endothelium in pulmonary vasculature in PAH, 2ME 
behaves as biological antagonist of estradiol (E2). 2ME and E2 have opposite effects on key regulators of 
angioproliferation (p27Kip1, AKT, HIF1-α, VEGF), and 2ME is a more potent modulator of prostacyclin, 
endothelin, and nitric oxide synthesis/release than E2.
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Warburg effect has been explored as a potential anti-angiogenic target in cancer and 
more recently in PAH. The HIF-1α transcription factor has been identified as a mas-
ter hypoxic regulator responsible for the metabolic shift in PAH [101, 109]. Hypoxic 
induction of HIF-1α leads to overexpression of pyruvate dehydrogenase kinase 
(PDK) which results in inhibition of pyruvate dehydrogenase that shunts pyruvate 
into glycolysis and induces conversion of glucose to lactate [108]. Dichloroacetate 
(DCA), a PDK inhibitor, reverses the Warburg effect and exhibits therapeutic 
effects in several animal models of PH [110–112]. Because 2ME is a strong HIF-1α 
inhibitor, 2ME should induce metabolic reprograming in PAH. Presently, the effects 
of 2ME on metabolic reprograming in PAH are unknown. However, 2ME inhibits 
lactate-induced mitochondrial biogenesis in highly proliferative osteosarcoma cells, 
and in apoptosis-resistant melanoma cells, 2ME attenuates proliferation and glycol-
ysis by inhibiting HIF-1α and PDK expression [113–115]. Therefore, 2ME could be 
viewed as modulator of metabolic reprograming. Further studies are warranted to 
investigate the effects of 2ME on the Warburg effect that in PAH is associated with 
highly proliferative, angiogenic, and apoptosis-resistant phenotypes (Figure 4).
5. Anti-inflammatory and immunomodulatory effects of 2ME
Inflammation and altered immunity, i.e., perivascular accumulation of inflamma-
tory and immune cells in pulmonary circulation, have been increasingly recognized 
as pathogenic factors in PAH [17–19]. In this regard, at young age women have more 
robust immune responses than men. Although initially beneficial, with aging these 
aggressive immune responses may become detrimental [116]. This may explain why 
various immune diseases are remarkably more frequent in women and why many 
immune diseases, such as systemic sclerosis (SSc), lupus, and mixed connective 
tissue disease, are associated with increased risk of PAH [117]. Furthermore, recently 
distinct immune phenotypes have been reported in PAH patients [118]. In experi-
mental PH, dysregulated immunity in the form of deficient regulatory T-cell (Treg) 
activity contributes to increased inflammation [20]. Both alveolar macrophages 
and immune cells express steroidogenic enzymes including sulfatase and aroma-
tase [119–121]. Inflammatory cytokines, prostanoids, and growth factors regulate 
the expression and activity of steroidogenic enzymes, and in turn, sex hormones 
Figure 4. 
Cellular effects of 2ME that contributes to the reduced E2 production, inflammation, angioproliferation, 
metabolic reprograming, and vascular and right ventricular remodeling in PAH.
92-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier
DOI: http://dx.doi.org/10.5772/intechopen.86812
may influence the production and release of these autocrine/paracrine mediators 
[122]. E2 upregulates CYP1B1, aromatase, and sulfatase activity and inhibits sEH 
activity. Therefore, in an inflammatory environment, E2 may boost its own produc-
tion, and via a feed-forward mechanism, E2 may enhance the production of pro-
inflammatory, angiogenic, and mitogenic estrogens and increase the accumulation 
of pro-inflammatory arachidonic acid metabolites (Figure 2). In contrast to E2, 
non-estrogenic 2ME exhibits significant anti-inflammatory effects, largely through 
suppression of tissue recruitment and activation of macrophages [123, 124]. This 
is one of the most consistent in vivo effects of 2ME seen in experimental models of 
cardiovascular and renal injury [125, 126] and in pulmonary hypertension [50, 51, 
127–129]. 2ME, its metabolic precursor 2HE, and the synthetic analog 2-ethoxyestra-
diol inhibit influx and activation of macrophages in MCT- and bleomycin-induced 
PH, and this inhibition correlates with reduced PH, vascular remodeling, and 
fibrosis. 2ME and its metabolic precursor 2HE also inhibit the synthesis of leukotri-
enes [130]. Blocking of leukotriene production by macrophages prevents endothelial 
injury and reverses experimental PH [131]. In experimental autoimmune rheumatoid 
arthritis, 2ME slows down disease progression by inhibiting inflammatory cytokine 
mRNA (IL-1β, TNF-α, IL-6, and IL-17), leucocyte infiltration, and neovasculariza-
tion [31]. In several models of autoimmune inflammatory disease, the beneficial 
effects of 2ME were ascribed to the inhibition of immune cell activation, prolifera-
tion, and pro-inflammatory cytokine release [31, 132–134]. Finally, in fibroblasts 
from SSc disease patients that are at high risk for developing PAH, 2ME reduces 
hypoxia-induced production of connective tissue growth factor and collagen I by 
inhibiting the PI3K/Akt/mTOR or HIFα signaling [135]. Collectively, these data in 
inflammatory and autoimmune diseases point toward 2ME as potential modulator of 
inflammation and immunity relevant to the development and progression of PAH.
6. 2-Methoxyestradiol and the renin-angiotensin system (RAS) in PAH
Evidence suggests that the renin-angiotensin system (RAS) contributes to the 
development of PAH [136, 137]. For example, (1) there is increased systemic RAS 
activity in patients with idiopathic PAH; (2) in experimental and human PH, ACE 
activity and expression are increased in PAECs, PVSMCs, plexiform lesions, and 
the RV; (3) increased Ang II type 1 receptor expression and signaling correlates 
with PAH progression and vascular remodeling [137–142]; and (4) inhibition of 
RAS slows down the progression of MCT-induced PH [143]. Cumulating data also 
suggests that 2ME may behave as biological antagonist of Ang II. 2ME downregu-
lates Ang II type I receptors [144–146]. In COMT−/− mice that have reduced 2ME 
production, 2ME treatment abolishes hypersensitivity to and injury induced by 
Ang II [65]. Furthermore, in Cyp1B1−/− mice that also have reduced 2ME produc-
tion, 2ME treatment abolishes Ang II-induced oxidative and vascular injury [147]. 
Finally, of relevance in PAH, in vivo in high RAS activity models, 2ME attenuates 
Ang II-induced cardiac and vascular remodeling and fibrosis and isoproterenol-
induced RV and LV hypertrophy and fibrosis [148].
7. Role of 2ME and the metabolic syndrome in PAH
The metabolic syndrome (MS) is recognized as risk factor for PH [149, 150]. 
Deficiency in PPARγ (a downstream target of BMPR2) and deficiency in apolipo-
protein E and adiponectin (downstream targets of PPARγ) have been linked to the 
development of PH in rodents [151–153]. Moreover, COMT, via methoxyestradiols, 
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has been identified as a major factor modulating insulin resistance. The low-activity 
COMT158Val-Met is linked to MS [154], whereas high-activity COMT rs4680 is 
associated with lower HbA1c levels and protection from type 2 diabetes [155]. COMT 
deficiency in mice leads to disrupted glucose homeostasis [66], and 2ME which 
shares structural similarity with PPARγ ligands and acts as a PPARγ agonist [65, 
156] (Figure 4) induces AMPK phosphorylation and improves insulin sensitivity 
in COMT−/− mice [66]. 2HE, a metabolic precursor of 2ME and COMT substrate, 
activates AMPK in human skeletal muscle, attenuates experimental PH in lean rats, 
and reduces MS-induced endothelial dysfunction in obese rats. Moreover, in rats 
with polygenic obesity and MS, in both PH-free females and PH male ZDSD rats, 
treatment with 2HE reduces glycosylated hemoglobin, RVPSP, and RV-EDP and 
attenuates vascular remodeling in male PH rats [157]. These data warrant further 
investigation of 2ME in MS-induced PH and support the notion of 2ME as potential 
disease modifier in MS-related PH.
8. 2-Methoxyestradiol and current pharmacotherapy of PAH
Despite significant advances in pharmacotherapy of PAH, mortality of patients with 
PAH remains high. Therefore, there is still a significant unmet medical need for more 
effective therapies. Currently approved drugs for treatment of PAH include medica-
tions that correct for prostanoid deficiency (prostanoids and prostacyclin receptor 
agonists) and deficiency of nitric oxide (PDE5 inhibitors and soluble guanylate cyclase 
stimulators) or combat overproduction of endothelin (endothelin receptor antago-
nists). Compared to ECs in healthy vessels, the ECs in affected vessels in PH show 
reduced prostacyclin and nitric oxide synthesis and overexpression of ET-1 [158–160]. 
Noteworthy, compared to estradiol, 2ME is a more potent inhibitor of endothelin syn-
thesis in endothelial cells [48, 161], and 2ME and its metabolic precursor 2HE inhibit 
endothelin-induced vasoconstriction [162]. Furthermore, in ECs 2ME is a more potent 
stimulator of prostacyclin synthesis than estradiol [163, 164]. 2ME also increases basal 
and potentiates stimulated NO production in male and OVX female rats, but has no 
effect in intact females, and in vitro these effects are abolished by the eNOS inhibitor 
L-NAME [165]. 2ME induces vasodilation by stimulating NO release via PPARγ/PI3K/
Akt pathway [166] and increases NO production in uterine artery ECs from pregnant 
sheep [167]. Moreover, in L-NAME-treated rats, 2ME attenuates severe hypertension 
and renal, cardiac, and vascular injury and inflammation and reduces mortality by 87% 
[125]. Likewise, 2ME exhibits beneficial effects in MCT-induced PH and efficacy com-
parable to that of bosentan and sildenafil. Importantly, in combination with bosentan 
or sildenafil, 2ME has synergistic therapeutic effects (further reduces vascular remod-
eling, inflammatory responses, and survival) [128]. Finally, none of the approved 
therapies for PAH affects endothelial remodeling and “dysregulated angiogenesis” in 
pulmonary vasculature; in contrast, as discussed above in Section 3, 2ME is a strong 
anti-angiogenic agent and inhibitor of HIF-VEGF axis that is critical for the metabolic 
shift and development of occlusive and complex vascular lesions. Altogether, these 
data clearly indicate 2ME as a promising pharmacological agent capable of providing 
additional benefit in PAH patients on standard single or combination therapy.
9.  Pharmacokinetic aspects of the development of 2ME as a disease 
modifier in PAH
The safety and efficacy of 2ME in human PAH are unknown. However, over the 
past two decades, numerous phase I and II clinical trials have been conducted to test 
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the safety and antitumor efficacy of 2ME in patients with solid malignancies. These 
studies show that 2ME is well tolerated and safe in doses up to 3 g/day. Unfortunately, 
even high oral doses of 2ME achieve only low plasma 2ME concentrations due to high 
pre-systemic metabolism (glucuronidation) in the liver. In experimental PH, thera-
peutic effects of 2ME are achieved by much lower doses (240 μg/kg/day) delivered 
by subcutaneous micro-infusions that produce high physiological concentrations of 
2ME (~3 ng/ml; equivalent to levels observed during the last trimester of pregnancy) 
[168]. At these concentrations, 2ME does not induce estrogenic effects. In rats with 
MCT-induced PH, although higher doses of 2ME do not additionally reduce PH and 
RV hypertrophy, higher doses do further inhibit media remodeling and inflamma-
tion [127]. Likewise, in contrast to oral administration in healthy volunteers and 
cancer patients, subcutaneous administration of a long-acting formulation of 2ME in 
doses up to 10 mg produced blood levels of 2ME >1 ng/ml over a 3-week period, with 
no estrogenic or other adverse effects reported [169]. Currently, various parenteral 
formulations of 2ME with supposedly high bioavailability are under investigation.
10. Conclusions and future directions
An expanding body of knowledge indicates that many of the beneficial cellular 
and systemic effects of E2 are due, at least in part, to its major and non-estrogenic 
metabolite 2ME. This underscores the importance of estradiol metabolism to 2ME 
in women’s health and suggests that 2ME deficiency may contribute to many female 
predominant diseases, including PAH. 2ME should not be viewed only as partial 
mediator of E2 effects but in PAH should be considered a moderator of the harmful 
effects of estrogens related to several key events in PAH including altered estradiol 
and arachidonic acid metabolism, angiogenesis, inflammation, harmful immune 
responses, metabolic syndrome, and metabolic reprograming. The above discussion 
hopefully makes the case for 2ME as unrecognized disease modifier in PAH.
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